EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Scopolamine reduces postoperative anxiety and depression in high-risk patients undergoing gynecological surgery: a randomized placebo-controlled clinical trial

Shaoting Zhang, Guangyan Zhang, Haihua Shu, Zhimin Guo, Lu Chang, Li Mei, Jia Zhan, Jue Ma, Fei Zhong

Frontiers in Psychiatry · 20.11.2026 · 17

DOI: 10.3389/fpsyt.2026.1800530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Psychiatry, online erschienen am 20.11.2026. Verfasst von Shaoting Zhang und 8 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Scopolamine is a commonly used preoperative anticholinergic drug. Previous studies have reported anxiolytic and antidepressant effects of scopolamine in both animal models and clinical populations. However, these effects have not been sufficiently studied in the context of perioperative anxiety and depression. This study aims to evaluate the impact of scopolamine on perioperative anxiety and depression in a high-risk population undergoing gynecological surgery.

Methods

Preoperative anxiety and depression were assessed using the Hospital Anxiety and Depression Scale (HADS) in patients scheduled for gynecological surgery. Patients who exhibited symptoms of anxiety or depression were randomly assigned to receive either intravenous scopolamine (0.3 mg) or saline placebo. The primary outcome was the change in HADS scores at postoperative day (POD) 7. Secondary outcomes included changes in HADS scores at PODs 1, 3, and 7 separately, as well as scores on the Pittsburgh Sleep Quality Index (PSQI), medication-related side effects, and postoperative adverse events.

Results

Among 583 screened patients, 128 presented with preoperative anxiety or depression symptoms and were included in the analysis. In the scopolamine group, the mean anxiety score (HADS-A) decreased by 1.43 points at POD 7, compared to a decrease of 0.33 points in the placebo group [95% confidence interval (CI) of difference between the two groups: 0.73 to 1.47]. Similarly, the mean depression score (HADS-D) in the scopolamine group decreased by 0.43 points, compared to a decrease of 0.08 points in the placebo group [95% confidence interval (CI) of difference between the two groups: 0.02 to 0.68].

Conclusions

Administration of scopolamine was associated with a significant reduction in postoperative anxiety and depression scores among patients undergoing gynecological surgery who were at high risk for these conditions. Clinical trial registration https://www.chictr.org.cn/showproj.html?proj=135227 , identifier ChiCTR2100051997.

Zitieren

APA

Zhang, S., Zhang, G., Shu, H., Guo, Z., Chang, L., Mei, L., Zhan, J., Ma, J., & Zhong, F. (2026). Scopolamine reduces postoperative anxiety and depression in high-risk patients undergoing gynecological surgery: a randomized placebo-controlled clinical trial. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1800530

Vancouver

Zhang S, Zhang G, Shu H, Guo Z, Chang L, Mei L, et al. Scopolamine reduces postoperative anxiety and depression in high-risk patients undergoing gynecological surgery: a randomized placebo-controlled clinical trial. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.1800530

BibTeX
@article{Zhang2026,
  author = {Zhang, Shaoting and Zhang, Guangyan and Shu, Haihua and Guo, Zhimin and Chang, Lu and Mei, Li and Zhan, Jia and Ma, Jue and Zhong, Fei},
  title = {Scopolamine reduces postoperative anxiety and depression in high-risk patients undergoing gynecological surgery: a randomized placebo-controlled clinical trial},
  journal = {Frontiers in Psychiatry},
  year = {2026},
  volume = {17},
  doi = {10.3389/fpsyt.2026.1800530}
}
Kostenlos starten →